ME
FLGT icon

McIlrath & Eck’s Fulgent Genetics FLGT Stock Holding History

McIlrath & Eck’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28
Closed -$608 – 998
2024
Q3 		$608 Hold
28
– – ﹤0.01% 930
2024
Q2 		$549 Hold
28
– – ﹤0.01% 899
2024
Q1 		$608 Hold
28
– – ﹤0.01% 887
2023
Q4 		$809 Hold
28
– – ﹤0.01% 862
2023
Q3 		$749 Hold
28
– – ﹤0.01% 829
2023
Q2 		$1.04K Hold
28
– – ﹤0.01% 820
2023
Q1 		$874 Hold
28
– – ﹤0.01% 850
2022
Q4 		$834 Hold
28
– – ﹤0.01% 811
2022
Q3 		$1K Hold
28
– – ﹤0.01% 796
2022
Q2 		$2K Hold
28
– – ﹤0.01% 738
2022
Q1 		$2K Hold
28
– – ﹤0.01% 725
2021
Q4 		$3K Hold
28
– – ﹤0.01% 692
2021
Q3 		$3K Hold
28
– – ﹤0.01% 690
2021
Q2 		$3K Hold
28
– – ﹤0.01% 688
2021
Q1 		$3K Buy
+28
New +$2.89K ﹤0.01% 654

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

McIlrath & Eck's FLGT Position: Q4 2024 in Review

McIlrath & Eck sold out of Fulgent Genetics (FLGT) in Q4 2024, closing a stake of 28 shares — an estimated $608 sold.

McIlrath & Eck first reported a position in FLGT in Q1 2021 and held it in 15 quarters. The position peaked at $3K in Q4 2021. 189 funds tracked by Wall St. Rank hold FLGT as of Q4 2024.

  • McIlrath & Eck reported no remaining Fulgent Genetics position as of Q4 2024 after selling out during the quarter.
  • McIlrath & Eck sold 28 Fulgent Genetics shares in Q4 2024, an estimated $608.
  • McIlrath & Eck first reported a position in Fulgent Genetics in Q1 2021 and held it in 15 quarters.
  • McIlrath & Eck's Fulgent Genetics position peaked at $3K in Q4 2021.
  • 189 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2024.

Based on McIlrath & Eck's 13F filing for Q4 2024, filed 18 Feb 2025.